ATE320005T1 - Testverfahren für agonisten oder antagonisten der bindung von dynorphin a an den mas-rezeptor - Google Patents
Testverfahren für agonisten oder antagonisten der bindung von dynorphin a an den mas-rezeptorInfo
- Publication number
- ATE320005T1 ATE320005T1 AT01272423T AT01272423T ATE320005T1 AT E320005 T1 ATE320005 T1 AT E320005T1 AT 01272423 T AT01272423 T AT 01272423T AT 01272423 T AT01272423 T AT 01272423T AT E320005 T1 ATE320005 T1 AT E320005T1
- Authority
- AT
- Austria
- Prior art keywords
- dynorphin
- agonists
- antagonists
- binding
- testing methods
- Prior art date
Links
- 108010065372 Dynorphins Proteins 0.000 title abstract 3
- 239000000556 agonist Substances 0.000 title abstract 3
- JMNJYGMAUMANNW-FIXZTSJVSA-N dynorphin a Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 JMNJYGMAUMANNW-FIXZTSJVSA-N 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title abstract 2
- 102100024622 Proenkephalin-B Human genes 0.000 title 1
- 238000012360 testing method Methods 0.000 title 1
- 102400000242 Dynorphin A(1-17) Human genes 0.000 abstract 2
- 238000003556 assay Methods 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9486—Analgesics, e.g. opiates, aspirine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/665—Assays involving proteins derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25797700P | 2000-12-22 | 2000-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE320005T1 true ATE320005T1 (de) | 2006-03-15 |
Family
ID=22978581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01272423T ATE320005T1 (de) | 2000-12-22 | 2001-12-19 | Testverfahren für agonisten oder antagonisten der bindung von dynorphin a an den mas-rezeptor |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7078177B2 (de) |
| EP (1) | EP1346221B1 (de) |
| JP (1) | JP2004516036A (de) |
| AT (1) | ATE320005T1 (de) |
| CA (1) | CA2430719A1 (de) |
| DE (1) | DE60117701T2 (de) |
| WO (1) | WO2002052267A1 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0502497A (pt) * | 2005-06-28 | 2007-02-06 | Univ Minas Gerais | uso de agonistas e antagonistas do receptor acoplado a proteìna g, mas, como moduladores de atividade apoptótica para o estudo, a prevenção e o tratamento de doenças |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5017689A (en) * | 1989-07-06 | 1991-05-21 | Arizona Technology Development Corporation | Dynorphin analogs specific for kappa opioid receptors |
| SE9704836D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Pharma Inc | Novel receptor |
-
2001
- 2001-12-19 CA CA002430719A patent/CA2430719A1/en not_active Abandoned
- 2001-12-19 US US10/250,629 patent/US7078177B2/en not_active Expired - Fee Related
- 2001-12-19 EP EP01272423A patent/EP1346221B1/de not_active Expired - Lifetime
- 2001-12-19 AT AT01272423T patent/ATE320005T1/de not_active IP Right Cessation
- 2001-12-19 JP JP2002553115A patent/JP2004516036A/ja active Pending
- 2001-12-19 WO PCT/SE2001/002854 patent/WO2002052267A1/en not_active Ceased
- 2001-12-19 DE DE60117701T patent/DE60117701T2/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE60117701T2 (de) | 2006-09-21 |
| US7078177B2 (en) | 2006-07-18 |
| EP1346221B1 (de) | 2006-03-08 |
| EP1346221A1 (de) | 2003-09-24 |
| WO2002052267A1 (en) | 2002-07-04 |
| US20040171080A1 (en) | 2004-09-02 |
| DE60117701D1 (de) | 2006-05-04 |
| CA2430719A1 (en) | 2002-07-04 |
| JP2004516036A (ja) | 2004-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69835225D1 (de) | Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen | |
| ATE377606T1 (de) | Zyklische antagonisten der c5a rezeptoren sowie der g-protein gekoppelten rezeptoren | |
| ATE286897T1 (de) | Morpholinderivate als antagonisten an orexinrezeptoren | |
| MX9203401A (es) | Anticuerpos antagonistas de la interleukina-4 humana. | |
| ATE312811T1 (de) | Benzamidinderivate als antagonisten von orexinrezeptoren | |
| DE60336901D1 (de) | Chinazolinon modulatoren von nukleinrezeptoren | |
| DE60308870D1 (de) | Kompensation von testsignalverschlechterung aufgrund der dut fehlfunktion | |
| EA200501724A1 (ru) | Соединения, специфичные к меланокортиновым рецепторам | |
| UY27760A1 (es) | Nuevos derivados de pirrolidinio. | |
| CY2010010I1 (el) | Ανταγωνιστες με βαση υποδοχεα il-1 και μεθοδοι κατασκευης και χρησης | |
| ATE343591T1 (de) | Antagonist für die multimerisierung von hiv-1 vif-protein | |
| AR028983A1 (es) | Composiciones farmaceuticas que contienen nicotina o un ligando de los receptores nicotinicos y un inhibidor de la monoamina oxidasa y su aplicacion en la abstinencia de tabaco | |
| ATE484231T1 (de) | Vorrichtung für vorhersage von muskel/skelett- erkrankungen | |
| EA199900630A1 (ru) | Антагонисты рецепторов витронектина | |
| ES2186704T3 (es) | Uso de antagonistas de crf. | |
| NO20003221L (no) | Ny G-proteinkoblet reseptor | |
| MXPA04001287A (es) | Ensayo de receptor unido a proteina g. | |
| ATE317699T1 (de) | Glucocorticoid receptor antagonisten zur behandlung von demenz | |
| ATE306272T1 (de) | Verwendung von einem aldosteron-rezeptor- antagonisten zur verbesserung der kognitiven funktion | |
| DE112005001558A5 (de) | Verfahren für den Nachweis der Herkunft von Banknoten | |
| DE69915113D1 (de) | 5ht1 rezeptor antagonisten und ihre verwendung für die behandlung von depression | |
| DE60210989D1 (de) | Der ligand für den g-protein gekoppelten rezeptor gpr86 und seine verwendungen | |
| DE60117701D1 (de) | Testverfahren für agonisten oder antagonisten der bindung von dynorphin a an den mas-rezeptor | |
| DK0862627T3 (da) | Neuropeptid Y-Y5 receptor | |
| NO20006320L (no) | Cykliske somatostatin-analoger |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |